目的:观察电针联合棕榈酸帕潘立酮长效注射液(PP-LAI)对甲基苯丙胺(MA)成瘾者戒断症状及神经递质的影响。
方法:共有109名甲基苯丙胺成瘾者,从2021年10月至2022年10月在医院接受治疗的人被选中。根据随机数表,将患者分为研究组(n=54)和对照组(n=55),其中对照组采用PP-LAI治疗,研究组在对照组基础上采用电针治疗;治疗前及治疗后12个月内采用甲基苯丙胺戒断症状评分量表评定疗效;γ-氨基丁酸,血清素,比较两组的乙酰胆碱值。
结果:1)两组治疗前MA戒断症状评分无统计学差异(p>0.05);2)研究组治疗3、6个月后MA戒断症状评分与对照组比较差异有统计学意义;3)治疗6个月后研究组多巴胺水平明显高于对照组,和γ-氨基丁酸值及5-羟色胺值均显著低于对照组(p<0.05)。
结论:电针联合PP-LAI可部分改善甲基苯丙胺成瘾者的戒断症状和焦虑。这是预防戒断症状复发的潜在治疗方法。
OBJECTIVE: To investigate the effects of electroacupuncture combined with paliperidone palmitate long-acting injection (PP-LAI) on withdrawal symptoms and neurotransmitters in methamphetamine (MA) addicts.
METHODS: A total of 109 methamphetamine addicts, who were treated in the hospital from October 2021 to October 2022, were selected. According to the random number table, the patients were divided into the study group (n=54) and the control group (n=55), in which the control group was treated with PP-LAI and the study group was treated with electroacupuncture on the basis of the control group; the methamphetamine withdrawal symptom score scale was used to assess the therapeutic effect before treatment and within 12 months after treatment; the changes of brain neurotransmitters dopamine, γ-aminobutyric acid, serotonin, acetylcholine values were compared between the two groups.
RESULTS: 1) There was no statistical difference in MA withdrawal symptom scores between the two groups before treatment (p>0.05); 2) MA withdrawal symptom scores have a statistically significant difference between the study group and the control group after 3 and 6 months of treatment; 3) dopamine levels in the study group were significantly higher than those in the control group after 6 months of completion of treatment, and γ-aminobutyric acid values and 5- serotonin values in the study group were significantly lower than those in the control group (p<0.05).
CONCLUSIONS: Electroacupuncture combined with PP-LAI can partially improve the withdrawal symptoms and anxiety of methamphetamine addicts. This is a potential treatment for preventing relapse of withdrawal symptoms.